Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma

Taxiarchis V. Kourelis, Morie Gertz, Clive Zent, Martha Lacy, Robert Kyle, Prashant Kapoor, Steven Zeldenrust, Francis Buadi, Thomas Witzig, Suzanne Hayman, John Lust, Stephen Russell, Yi Lin, Vincent S. Rajkumar, Shaji Kumar, Nelson Leung, David Dingli, Angela Dispenzieri

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


To clarify the presentation and course of patients with chronic lymphocytic leukemia (CLL) and amyloidosis. Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated at Mayo Clinic, Rochester from January 1974 to October 2012. Charts were abstracted and data analyzed. Of the 33 patients identified, 20 (61%) were diagnosed with AL and 13 (39%) with non-AL. Only four patients had immunoglobulin light chain amyloidosis (AL) that could be solely attributed to the CLL clone; another six had both a plasma cell clone and a CLL clone that shared the same light chain. Median overall survival was 15.6 months for patients with AL and 58.1 months for patients with non-AL. For patients with AL management involved chemotherapy targeted toward monoclonal plasma cells, lymphocytes or both, and for patients with non-AL no specific amyloid treatment was administered. AL is a rare complication of CLL, but in this elderly population of patients non-AL is nearly as common. Distinguishing between these two groups is essential since patients with non-AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis.

Original languageEnglish (US)
Pages (from-to)375-378
Number of pages4
JournalAmerican journal of hematology
Issue number5
StatePublished - May 2013

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma'. Together they form a unique fingerprint.

Cite this